Advancing Structural Heart Innovation at New York Valves 2025
P&F was proud to participate in this yearโs New York Valves Conference, held from June 25 to 28, 2025โa premier gathering focused on the latest advances in valvular and structural heart disease. Bringing together a multidisciplinary audience of cardiologists, interventionalists, and clinical leaders, the event served as a powerful platform for exchanging ideas, sharing clinical experiences, and spotlighting innovative therapies that are shaping the future of patient care.
Our teamโKatharina Kiss, Vrushali Tembe, Guilherme Agreli, Paul Shelton, and Arjun Bhatโwas on the ground throughout the week, engaging in meaningful conversations, attending key sessions, and showcasing our commitment to the evolution of transcatheter valve therapies.
Kicking Off with the TRICAV Investigatorโs Meeting
The conference began with a major milestone: the TRICAV investigatorโs meeting on June 25th. This gathering brought together clinical investigators and thought leaders to discuss trial progress, share insights, and align on the next steps in our shared mission to bring innovative tricuspid valve solutions to patients in need. It was a powerful reminder of the importance of collaboration in advancing research and improving outcomes.
Connecting with the Community
Throughout the conference, our team held one-on-one meetings with key opinion leaders, customers, and partners. These conversations are vital for gathering real-world feedback, identifying unmet needs, and building the partnerships that will drive the next wave of innovation in structural heart disease.
Looking Ahead
Events like New York Valves offer more than just educationโthey provide inspiration. They remind us why we do what we do: to push the boundaries of whatโs possible in cardiac care and deliver better solutions for patients worldwide. Weโre grateful for the opportunity to contribute and connect, and we look forward to continuing the momentum throughout the year.
